ICP-332 Tablets

DRUG5 trials

Sponsors

InnoCare Pharma Inc., Beijing InnoCare Pharma Tech Co., Ltd.

Conditions

Atopic DermatitisChronic Spontaneous Urticaria (CSU)Healthy SubjectsNon Segmental VitiligoPlaque Psoriasis

Phase 1

Phase I Study of ICP-332 in Healthy Subjects

CompletedNCT06530966

InnoCare Pharma Inc.Healthy Subjects

Start: 2024-07-23End: 2024-11-08Updated: 2026-04-14

Phase 2

ICP-332 in Subjects With Non-segmental Vitiligo

RecruitingNCT07047612

Beijing InnoCare Pharma Tech Co., Ltd.Non Segmental Vitiligo

Start: 2025-05-09End: 2029-04-30Target: 603Updated: 2025-08-07

Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis

RecruitingNCT07251998

Beijing InnoCare Pharma Tech Co., Ltd.Plaque Psoriasis

Start: 2025-12-22End: 2027-05-31Target: 172Updated: 2025-12-31

Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria

RecruitingNCT07378527

Beijing InnoCare Pharma Tech Co., Ltd.Chronic Spontaneous Urticaria (CSU)

Start: 2026-02-13End: 2028-09-01Target: 344Updated: 2026-04-21

Phase 3

ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis

RecruitingNCT06775860

Beijing InnoCare Pharma Tech Co., Ltd.Atopic Dermatitis

Start: 2024-11-14End: 2026-12-25Target: 552Updated: 2025-09-08